Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. - Wikidata - wikimedia - TriplyDB

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

http://www.wikidata.org/entity/Q33854022

about

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Colesevelam for type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus Diabetes Dyslipidemia Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.Cardiovascular safety profile of currently available diabetic drugs.Consensus statement on management of dyslipidemia in Indian subjects.Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.Update on Safety Issues Related to Antihyperglycemic Therapy Therapeutic targeting of bile acids Increased Bile Acid Synthesis and Impaired Bile Acid Transport in Human Obesity.Mechanisms of current therapies for diabetes mellitus type 2 Safety review of combination drugs for hyperlipidemia.A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?Clinical management of elderly patients with type 2 diabetes mellitus.Advances in pharmacologic therapies for type 2 diabetes.Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.Demystifying the management of hypertriglyceridaemia.Risks and benefits of statin use in young people with type 1 diabetes.Combination therapy when metformin is not an option for type 2 diabetes.A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Bile acids in glucose metabolism in health and disease.Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus.Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

P2860

Q22241288-475BC472-1DC8-47A1-B41E-5F1E2384FE76 Q24202334-5F8379DE-279D-43CA-A864-82071C32F759 Q24236703-26F9EC3A-9B1C-4D0C-AD42-2B9B06AD7053 Q26750905-92D25273-92B5-4F65-BCD9-A6CDA1239134 Q27324038-FE6DB4BE-E34C-4896-972D-82903FBEACB6 Q28068120-297858A6-DF47-4924-AC9E-77E45AAF03AF Q28084156-46A1E758-71F6-4740-8F62-870DA1432F1C Q30249371-34227938-12F0-4252-B5A5-886C3C048526 Q30377441-8F6560B7-190A-48FB-B2BB-9B4D3BCFFC41 Q33776230-42C372DC-A9F6-4F60-A64D-BFB02EEB5777 Q34081331-A74DBDE7-6E15-4689-8B10-A6B96596F8C4 Q34971736-B2253750-036A-4C82-A7AC-55255A3FEBB2 Q34980772-9839720E-2FAF-4A4A-9EC9-421BF9DC35A7 Q35309093-C6DD45B0-D6C4-4F52-856B-A8B209C4AEA7 Q35910429-E8B5DDC7-2E3C-49DC-B483-80724D14B679 Q35958534-9858E522-7392-405C-8DF4-B55E000102EF Q36911455-EF04E1D9-4E9E-47A9-A721-7646FD625047 Q37180829-8B467977-3AF5-48A2-AB7F-5765E866CC0C Q37854747-CAD9A3F9-2B49-434D-B1B7-5BB235060AE5 Q37890777-A2C23D01-35E3-4DE7-A023-92D024D26DF1 Q37923968-6C819D68-7E95-4544-A435-A5A0C5F7AB5B Q37982214-319ABEF3-8855-4354-93F4-FEAA759FBBDC Q38072616-B6BADDDD-4121-4005-8F47-E797F06BDDAD Q38136274-DA67C62E-8957-4A39-904B-DB76D3192247 Q38141575-C6621F96-BB66-460C-AD5F-1165940692DD Q38209424-B26F1254-4B12-4CA8-A0E2-F982DB49D5CF Q38377267-B7CEFFE2-0F4A-4AB0-B187-7A3044C007F0 Q38707493-16CB943C-E472-4146-B980-FB9BB1A09528 Q39160771-83A78257-1115-4D49-BB51-B9513291DF3B Q48042610-17572B07-D2CF-4032-99C5-BB28B43E6C54 Q50745656-EF5510FE-48C0-495D-AABA-A158E1395508 Q57412648-24173A0E-7A63-46F0-BA3F-0EA095F5C9DF

P2860

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

http://www.wikidata.org/entity/Q33854022

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@ast

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@en

type

label

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@ast

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@en

prefLabel

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@ast

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@en

P1433

Q33854022-6201ACE0-A794-489A-95EC-8B41F0015F15

P1476

Q33854022-84810D9D-4EE3-40EF-9411-2297E86C55E5

P2093

Q33854022-87096DF7-7E4B-418D-8738-23FE10360F87

Q33854022-AB397752-1239-42D8-B7D5-EF5D0D77CC87

P275

Q33854022-AE4AEAA5-BE07-4386-96EE-F22A232AB1E3

P2860

Q33854022-0967E489-C2D4-4BE2-8AA5-821D9AC520FB

Q33854022-16C757B5-9F15-4069-BF10-955718D34A58

Q33854022-2A1A0F01-C10B-4651-ACAB-C381D71E730F

Q33854022-2B6A4D40-9355-4676-A471-D7AD89EC8F8C

Q33854022-2F4B5406-95DE-4085-950E-41932D9DC17C

Q33854022-303BEBFF-6279-4EE2-A423-E5A0E00EFC2E

Q33854022-30DB9919-4790-4865-A34A-3A5FBBBDE96E

Q33854022-4198D489-5381-43C7-8AF3-CEE6C1F7010F

Q33854022-46849B0B-AF41-444C-A89B-051DA9FF38F5

Q33854022-4F640F64-D416-462C-9A33-6C2B63C1FE1F

P304

Q33854022-9FE26E34-0175-4F16-A162-23D379925563

P31

Q33854022-45073B98-A507-4548-BD0F-8AD0B6791EF2

Q33854022-93C29E91-23D6-46FC-BC61-AE543075E7BB

P356

Q33854022-34ECDC75-02E8-4407-88E4-66092D510BC0

P433

Q33854022-725F9416-3898-42F2-9CCF-93E29BBCEE91

P478

Q33854022-29DFC88A-F5EF-49CC-8B4F-F67C0F3CEE8D

P50

Q33854022-E32A7C53-16C6-497D-A9CF-D902FBFEF770

P5008

Q33854022-64ADCD18-7795-4293-A52F-E59FFA514323

P577

Q33854022-52EB447A-5EC5-40D4-8A3A-C8225C51E88C

P5875

Q33854022-49989FB5-64D1-4851-9300-7258E7405929

P698

Q33854022-486EA9CA-A4F6-4F23-A3B0-13487FAF3555

P921

Q33854022-086FE101-8B79-4071-A579-E51AA8AA8EB2

Q33854022-094967A0-6D48-40A3-82B8-B404748BE3C3

Q33854022-09B16541-F71E-41E4-BC5B-79F8253C4663

Q33854022-4C8BB5D9-9FFD-4989-BBCD-7CE4BC0BE17F

Q33854022-5E885DE8-5B1C-4369-8D03-7F959B05F38E

Q33854022-6F1B4E24-4135-47D0-8872-5AD57F58FE19

Q33854022-789ADCCB-FCE3-4E90-916E-5DB03F9B5B1E

Q33854022-E2AB99B8-4E74-4551-9B00-C99B097183E0

Q33854022-E69EC954-B727-409A-B4B3-15CCD36B2431

P932

Q33854022-46507D8F-959A-46B0-8C95-2ADA080666E9

P356

J.1463-1326.2009.01181.X

P1433

Diabetes, Obesity and Metabolism

P1476

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

@en

P2093

Vivian A Fonseca

http://www.w3.org/2001/XMLSchema#string

Yehuda Handelsman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice

Farnesoid X receptor is essential for normal glucose homeostasis

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

P304

384-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1463-1326.2009.01181.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43340233

http://www.w3.org/2001/XMLSchema#string

P698

20415686

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

type-2 diabetes

mechanism of action

cardiovascular disease

diabetic angiopathy

maturity-onset diabetes of the young

P932

2871173

http://www.w3.org/2001/XMLSchema#string